Business News

TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook

FinSiddhi

TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.

Related Posts

FIIs pour Rs 6,535 crore into Indian financial stocks. What else are they buying this month?

This month, foreign investors have significantly channeled capital into Indian financial stocks, while also increasing their investments in automobiles and consumer services, marking a clear shift in sector preference. Notably, healthcare and IT sectors have drawn substantial foreign interest, in contrast to sizeable foreign sell-offs in telecom and capital goods. This trend highlights a noticeable…

Stock Alert: TCS, ICICI Bank, Hindstan Copper, Afcons Infra, UCO Bank

SunShine Pictures will list today on the stock exchanges. The issue opened for bidding on 18 August 2026 and it closed on 20 August 2026. The price band of the IPO was fixed between Rs 342 and 360 per share. The offer received bids for 58.04 crore shares as against 54.86 lakh shares on offer….